Lycia Therapeutics, Inc. (LYCA) company profile
LYCANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.35+0.43 (+1.39%)
Close on Nov 18, 2026Market cap –P/E –Yield –
About Lycia Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Lycia Therapeutics, Inc. is listed on Nasdaq under the ticker LYCA, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31.
Company profile
Company
- Legal name
- Lycia Therapeutics, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 400 East Jamie Court, Suite 200 94080
- Phone
- (650) 392-3357
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- LYCA
- Exchange
- Nasdaq
- SEC CIK
- 1806540
- CUSIP
- 55081P100
- ISIN
- US55081P1003
- FIGI
- BBG00VDDDFT9
- Share class FIGI
- BBG00VDDDFV6
- EIN
- 84-3860514
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Aetna Wun Trombley | President and CEO, Director | 415,255 |
| Steven Staben | Chief Scientific Officer | 55,448 |
| Amy Bachrodt | Chief Financial Officer | – |
| Chin Hyok Lee | Chief Medical Officer | – |
| Sofia Touami | Chief Business Officer | – |
| William Jl Rieflin | Director | 89,781 |
| Jane Henderson | Director | – |
| Laurent Fischer | Director | 33,269 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 20, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?